Importantly, our study introduced the potential therapeutic approaches that disrupt the link between Zeb1-induced aerobic glycolysis and carcinogenesis, eventually leading to improvement of the clinical outcomes of patients with aggressive breast cancer. The gene discussed is ZEB1; the disease is breast cancer.